

S/N 09/825,765



PATENT

#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yumi Yokoyama et al.

Examiner: Unknown

Serial No.: 09/825,765

Group Art Unit: 1645

Filed: April 4, 2001

Docket: 600.491US2

Title: GENETIC MODIFICATION OF ENDOSTATIN

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

PRE AMENDMENT
AJ
PTX7
8-14-02

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed October 29, 2001, please amend the above-identified patent application as follows:

In the Specification

Please insert the SEQUENCE LISTING into the specification.

Please make the paragraph substitutions indicated in the appendix entitled "Clean Version of Amended Specification Paragraphs". The specific changes incorporated in the substitute paragraphs are shown in the following marked-up version of the original paragraphs:

The paragraph beginning at page 2, line 25 and continuing to page 3, line 23, is amended as follows:

The present invention provides a composition having a targeting moiety specific for endothelial cells linked to an antiangiogenic moiety. A "targeting moiety" as used herein is a molecule that facilitates the interaction and/or binding of the linked antiangiogenic moiety to endothelial cells. Preferably, the targeting moiety and the antiangiogenic moiety are polypeptides or peptides, which, when linked form a chimeric polypeptide. The term "chimeric polypeptide" refers to a protein that includes amino acid sequences or segments that are positioned or linked in a manner which does not normally occur in the native genome of a species. More preferably, the targeting moiety is a polypeptide or peptide derived from a particular extracellular matrix (ECM) polypeptide, such as human fibronectin. Fibronectin contains the tripeptide RGD (Arg-Gly-Asp), which is also found within most major types of